Mesenchymal stem cells in acute lung injury: are they ready for translational medicine?

Acute lung injury ( ALI ) is a severe clinical condition responsible for high mortality and the development of multiple organ dysfunctions, because of the lack of specific and effective therapies for ALI . Increasing evidence from pre‐clinical studies supports preventive and therapeutic effects of mesenchymal stem cells ( MSC s, also called mesenchymal stromal cells) in ALI / ARDS (acute respiratory distress syndrome). Therapeutic effects of MSC s were noticed in various delivery approaches (systemic, local, or other locations), multiple origins (bone marrow or other tissues), or different schedules of administrations (before or after the challenges). MSC s could reduce the over‐production of inflammatory mediators, leucocyte infiltration, tissue injury and pulmonary failure, and produce a number of benefit factors through interaction with other cells in the process of lung tissue repair. Thus, it is necessary to establish guidelines, standard operating procedures and evaluation criteria for translating MSC ‐based therapies into clinical application for patients with ALI .